These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 33949694)

  • 21. Development and validation of a nomogram for predicting the likelihood of metastasis in prostate cancer patients undergoing Ga-68 PSMA PET/CT due to biochemical recurrence.
    Coskun N; Kartal MO; Erdogan AS; Ozdemir E
    Nucl Med Commun; 2022 Aug; 43(8):952-958. PubMed ID: 35661662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Establishment of New Thresholds for PLND-Validated Clinical Nomograms to Predict Non-Regional Lymph Node Metastases: Using
    Jiao J; Quan Z; Zhang J; Wen W; Qin J; Yang L; Meng P; Jing Y; Ma S; Wu P; Han D; Davis AA; Ren J; Yang X; Kang F; Zhang Q; Wang J; Qin W
    Front Oncol; 2021; 11():658669. PubMed ID: 33937073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study.
    Meijer D; van Leeuwen PJ; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; van de Ven PM; van der Poel HG; Donswijk ML; Boellaard TN; Schoots IG; Oprea-Lager DE; Coughlin GD; Vis AN
    Eur Urol; 2021 Aug; 80(2):234-242. PubMed ID: 34024652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
    Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
    BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gallium-68-prostate-specific membrane antigen (
    van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
    BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
    BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and External Validation of a Novel Nomogram to Predict the Probability of Pelvic Lymph-node Metastases in Prostate Cancer Patients Using Magnetic Resonance Imaging and Molecular Imaging with Prostate-specific Membrane Antigen Positron Emission Tomography.
    Vis AN; Meijer D; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; van de Ven PM; Heymans MW; Nieuwenhuijzen JA; van der Poel HG; Donswijk ML; Boellaard TN; Schoots IG; Stricker P; Haynes AM; Oprea-Lager DE; Coughlin GD; van Leeuwen PJ
    Eur Urol Oncol; 2023 Dec; 6(6):553-563. PubMed ID: 37045707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer.
    Gondoputro W; Scheltema MJ; Blazevski A; Doan P; Thompson JE; Amin A; Geboers B; Agrawal S; Siriwardana A; Van Leeuwen PJ; van Oosterom MN; Van Leeuwen FWB; Emmett L; Stricker PD
    J Nucl Med; 2022 Nov; 63(11):1659-1664. PubMed ID: 35241483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
    Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
    Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction nomogram for
    Ceci F; Bianchi L; Borghesi M; Polverari G; Farolfi A; Briganti A; Schiavina R; Brunocilla E; Castellucci P; Fanti S
    Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):136-146. PubMed ID: 31492993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymph Node Involvement in Treatment-Naïve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management.
    Koerber SA; Stach G; Kratochwil C; Haefner MF; Rathke H; Herfarth K; Kopka K; Holland-Letz T; Choyke PL; Haberkorn U; Debus J; Giesel FL
    J Nucl Med; 2020 Jan; 61(1):46-50. PubMed ID: 31302638
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Esen T; Falay O; Tarim K; Armutlu A; Koseoglu E; Kilic M; Seymen H; Sarikaya AF; Kiremit MC; Balbay MD; Canda AE; Baydar DE; Kordan Y; Demirkol MO; Tilki D
    Eur Urol Focus; 2021 Mar; 7(2):288-293. PubMed ID: 33509671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.
    Budäus L; Leyh-Bannurah SR; Salomon G; Michl U; Heinzer H; Huland H; Graefen M; Steuber T; Rosenbaum C
    Eur Urol; 2016 Mar; 69(3):393-6. PubMed ID: 26116958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incremental Impact of [
    Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
    Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One-Stop-Shop Whole-Body
    Thalgott M; Düwel C; Rauscher I; Heck MM; Haller B; Gafita A; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    J Nucl Med; 2018 Dec; 59(12):1850-1856. PubMed ID: 29794224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization of prostate cancer patient lymph node staging via the integration of neutrophil-lymphocyte ratios, platelet-lymphocyte ratios, and
    Wang Y; Tang Y; Gao X; Gan Y; Hu S; Chen MF; Cai Y
    Prostate; 2022 Nov; 82(15):1415-1421. PubMed ID: 35860907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct Patlak Reconstruction of [
    Rasul S; Geist BK; Einspieler H; Fajkovic H; Shariat SF; Schmitl S; Mitterhauser M; Bartosch R; Langsteger W; Baltzer PAT; Beyer T; Ferrara D; Haug AR; Hacker M; Rausch I
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37761975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pelvic lymph node mapping in prostate cancer: examining the impact of PSMA PET/CT on radiotherapy decision-making in patients with node-positive disease.
    Furman B; Falick Michaeli T; Den R; Ben Haim S; Popovtzer A; Wygoda M; Blumenfeld P
    Cancer Imaging; 2024 Jul; 24(1):96. PubMed ID: 39075567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ga-68-PSMA PET/CT in treatment-naïve patients with prostate cancer: Which clinical parameters and risk stratification systems best predict PSMA-positive metastases?
    Rogasch JM; Cash H; Zschaeck S; Elezkurtaj S; Brenner W; Hamm B; Makowski M; Amthauer H; Furth C; Baur ADJ
    Prostate; 2018 Jul; ():. PubMed ID: 29978529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic performance of
    Zhang J; Shao S; Wu P; Liu D; Yang B; Han D; Li Y; Lin X; Song W; Cao M; Zhang J; Kang F; Qin W; Wang J
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):908-920. PubMed ID: 30635755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.